scholarly journals Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

2009 ◽  
Vol 101 (7) ◽  
pp. 1224-1224 ◽  
Author(s):  
A A M van der Veldt ◽  
E Boven ◽  
A J M van den Eertwegh ◽  
J B A G Haanen
Keyword(s):  
Renal Cell Cancer ◽  
Predictive Factors ◽  
Renal Cell ◽  
Cell Cancer ◽  
Severe Toxicity ◽  
Advanced Renal Cell Cancer

scholarly journals Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

2008 ◽  
Vol 99 (2) ◽  
pp. 259-265 ◽  
Author(s):  
A A M van der Veldt ◽  
E Boven ◽  
H H Helgason ◽  
M van Wouwe ◽  
J Berkhof ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Predictive Factors ◽  
Renal Cell ◽  
Cell Cancer ◽  
Severe Toxicity ◽  
Advanced Renal Cell Cancer

scholarly journals Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

2006 ◽  
Vol 17 (8) ◽  
pp. 1185-1196 ◽  
Author(s):  
P. Schöffski ◽  
H. Dumez ◽  
P. Clement ◽  
A. Hoeben ◽  
H. Prenen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

scholarly journals Markers of systemic inflammation predict survival in patients with advanced renal cell cancer

2013 ◽  
Vol 109 (1) ◽  
pp. 147-153 ◽  
Author(s):  
P Fox ◽  
M Hudson ◽  
C Brown ◽  
S Lord ◽  
V Gebski ◽  
...  
Keyword(s):  
Systemic Inflammation ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study

1998 ◽  
Vol 34 (5) ◽  
pp. 754-756 ◽  
Author(s):  
M Schuler ◽  
U Bruntsch ◽  
E Späth-Schwalbe ◽  
H Schrezenmeier ◽  
C Peschel ◽  
...  
Keyword(s):  
Phase Ii ◽  
Renal Cell Cancer ◽  
Interleukin 6 ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

scholarly journals Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 ◽  
Vol 19 (3) ◽  
pp. 405-415 ◽  
Author(s):  
Michael B Atkins ◽  
Elizabeth R Plimack ◽  
Igor Puzanov ◽  
Mayer N Fishman ◽  
David F McDermott ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Dose Finding ◽  
Open Label ◽  
Expansion Phase ◽  
Label Dose ◽  
Phase 1B ◽  
Advanced Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document